Medicare utilization — DR. LANCE FELLER (M.D.)
Calendar year 2023 · data refreshed 2026-05-27
| HCPCS | Description | Services | Beneficiaries | Allowed | Payment |
|---|---|---|---|---|---|
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 51,200 | 17 | $0 | $190,136 |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 5,435 | 12 | $0 | $173,905 |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | 469 | 237 | $0 | $41,506 |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 266 | 17 | $0 | $13,916 |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | 115 | 115 | $0 | $13,216 |
Service volume and Medicare payment amounts do not indicate quality of care, patient outcomes, or fraud. Data reflects Medicare fee-for-service only.
Source: CMS public data · Not endorsed by CMS · Beneficiary counts under 11 are suppressed in source data ·